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The advent of new antiretroviral drugs such as protease 
inhibitors has generated sensible changes in morbity and 
mortality in HIV-infected patients. Objectives: To evaluate 
the impact of Highly Active Antiretroviral Therapy (HAART) 
on the prevalence of chronic otitis media in HIV-infected 
pediatric population. Methods: We analyzed medical charts 
of 471 children aged zero to 12 years and 11 months with 
HIV infection from an Ambulatory of ENT and AIDS. Children 
were divided according to the age: 0 to 5 years and 11 months 
and 6 to 12 years and 11 months and classified as having 
chronic otitis media based on history, physical examination, 
audiologic and tympanometric data. Prevalence of chronic 
otitis media, as well as CD4+ lymphocyte count were 
compared between groups in use of HAART and the group 
without HAART. Results: Out of 459 children, 65 (14.2%) 
had chronic otitis media. We observed that in children aged 
0 to 5 years and 11 months who were taking HAART there 
was significant lower prevalence of chronic otitis media (p 
= 0.02). The use of HAART was associated to higher mean 
CD4+ lymphocyte count (p < 0.001). Conclusion: The use 
of HAART was associated to reduction in prevalence of 
chronic otitis media in HIV infected children, probably due 
to increase in mean CD4+ lymphocyte count.
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INTRODUCTION
The spread of HIV virus throughout the world has 
caused a terrible impact on childhood. It is estimated that 
2.2 million children bellow 15 years of age are infected, 
according to data from UNAIDS/WHO of 20041. In Brazil, 
until December of 2004, about 13,786 cases of children bel-
low 13 years of age had been registered by the Ministry of 
Health2. The discovery of new antiretroviral drugs, specially 
protease inhibitors have substantially reduced mortality 
and increased the life expectancy of these children3,4. Such 
condition, associated to the fact that many of the initial 
signs and symptoms of HIV infections are otorhinolaryn-
gological, has brought a greater number of these patients 
to be assessed by this medical specialty3,5.
Otitis media (OM) is a common disease in child-
hood, and it is the most frequent acute disease seen by 
pediatricians6. OM prevalence in HIV-positive children 
may reach 80%7, and the seropositive child is more prone 
to have the disease (and in a higher degree of severity), 
when compared to immunecompetent children8. Moreover, 
for the HIV-immunocompromised child, the ENT should 
consider potential complications secondary to the disease, 
affecting the middle ear9, such as otomastoiditis and Central 
Nervous System involvement.
In 1987, Zidovudine was developed, a nucleoside 
inhibitor, analogous to the reverse transcriptase enzime 
(Reverse Transcriptase Nucleoside Inhibitors - RTNI), 
thus becoming the number one drug for the treatment 
of AIDS. Following that, non-nucleoside inhibitors of 
the same enzime (RTNNI) were developed, and in 1996, 
new antiretroviral drugs were introduced, represented by 
Protease Inhibitors (PI)3. The combination of these new 
drug classes (usually 2 RTNI + 1 PI or 1 RTNI + 1 RTNNI 
+ 1 PI) started to be called Highly Active Antiretroviral 
Therapy - HAART).
Despite the high prevalence of OM in HIV-infected 
children, data related to a prevalence change in this dis-
ease in the pediatric population after the introduction of 
HAART remain scarce.
Thus, our major goal is to assess the changes asso-
ciated to the use of HAART on the prevalence of chronic 
otitis media on a certain layer of Brazilian children infected 
by HIV.
MATERIALS AND METHODS
We carried out a retrospective analysis on the charts 
of 471 children with prior diagnosis of HIV infection, with 
ages ranging between 0 and 12 years and 11 months, who 
were seen at the HIV/AIDS outpatient ward of the Otorhi-
nolaryngology Department of the University Hospital of the 
Medical School of the University of São Paulo (HC-FMUSP), 
between January of 1990 and December of 2004.
12 children who were not receiving antiretroviral 
medication were taken off the sample. The 459 patients 
included in the study were receiving therapy with at least 
one antiretroviral drug for at least 5 months: 236 used the 
regimen without protease inhibitors, making up group ART 
(Antiretroviral Therapy – ART) and 223 were in HAART. 
The average time of treatment among those patients 
under ART was of 14 ± 4 months; and among patients 
using HAART was of 9 ± 2 months. Demographics (age, 
gender, place of birth and HIV infection via), as well as 
the antiretroviral regimens used by these 459 children are 
presented on Table 1. Data on the immunological clas-
sification of these children were also collected from the 
charts, based on the 1994 Center for Disease Control ‘Re-
vised Classification System for Human Immunodeficiency 
Infection in Children Less than 13 Years of age’10, and are 
summarized on Table 2.
On the first ambulatorial consultation we carried 
out a complete otorhinolaryngological exam, always by 
the same specialist (IDM). Table 3 depicts the otorhino-
laryngological diagnosis of the 459 children studied. Oti-
tis media was the most common otorhinolaryngological 
disease found (present in 33.1% of the children), and less 
than one-fourth (22.5%) of the children did not have any 
Table 1. Demographics and anti-retroviral therapies used by the 459 
children infected.
Gender
Male 258 (56,2%)
Female 201 (43,8%)
Age
Average ± SD (years) 6,6 ± 2,5
0 to 5 years and 11 months 176 (38,3%)
6 to 12 years and 11 years 283 (61,7%)
HIV transmission means
Vertical 387 (84,3%)
Blood Transfusion 18 (3,9%)
Unknown 54 (11,7%)
Origin
Support institutions / hospitals 362 (79,0%)
Outpatient wards 97 (21,0%)
Anti-retroviral therapy
2 ITRN + IP 133 (29,0%)
ITRN + ITRNN + IP 90 (19,6%)
AZT + DDI 45 (9,8%)
AZT + 3TC 82 (17,9%)
AZT only 90 (19,6%)
DDI only 19 (4,2%)
ITRN = Nucleoside Reverse Transcriptase Inhibitors: Zidovudine (AZT), 
Didanosine (DDI), Lamivudine (3TC); IP = Protease Inhibitors: Indinavir, 
Ritonavir, Saquinavir, Nelfinavir; ITRNN = Non-nucleoside Reverse 
Transcriptase Inhibitors: Nevirapine, Efavirenz.
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otorhinolaryngological diagnosis.
In order to classify and diagnose otitis media as 
acute (AOM) or chronic (COM) or serous (SOM), we used 
the following criteria:
1. AOM: diagnosis based on clinical data (fever and 
ear ache or irritability of sudden onset for less than one 
week) and the findings from the pneumatic otoscopy: 
hyperemia or opacity in an intact tympanic membrane, 
followed by its bulging or loss of mobility6,11;
2. COM: the diagnosis was defined based on the 
presence of chronic inflammation of the middle ear and 
the mastoid mucosa, with a non-intact tympanic membrane 
and/or purulent otorrhea with a normal external auditory 
canal for more than six weeks6,12-14;
3. SOM: diagnosis was defined based on the 
evidence of serous-purulent effusion from the middle ear 
with an intact tympanic membrane and without active 
infection6,15, audiometry showing an air-bone gap and type 
B tympanometric curve.
On the same day of the first visit, a blood sample 
was collected in order to determine the serum count of 
CD4+ T lymphocytes.
Statistics
The analysis of these 459 children was stratified 
according to age, and they were divided in two groups: 
from 0 to 5 years and 11 months, and from 6 to 12 years 
and 11 months. For each age range we compared and 
calculated OM prevalence, as well as CD4 + T cells among 
the patients under ART and those under HAART. We used 
the Pearson’s chi-squared test and the Fisher test for cat-
egorical variables, and the non-parametric Mann-Whitney 
U test for the continuous variables. P values bellow 0.05 
were considered statistically significant. Data was analyzed 
through the Statistical Package for Social Sciences (SPSS® 
for Windows 10.0, SPSS Inc., Chicago, IL) software.
This study was evaluated and approved by the Eth-
ics in Research Committee of the Hospital.
RESULTS
Among the 459 children, 152 (33.1%) had some 
type of otitis media. The COM was the most prevalent in 
both age groups, present in 65 (14.2%) children. Table 4 
depicts the prevalence of chronic otitis media found and 
its distribution according to age and the use of HAART.
At the age range between 6 and 12 years and 11 
months, prevalence differences among the different types 
of otitis were not statistically significant among ART and 
HAART children. However, in the group of children with 
ages varying between 0 and 5 years and 11 months, the 
prevalence of chronic otitis media was significantly lower 
(p = 0.02). The relative risk of these children bellow 5 
years and 11 months of age under the HAART regimen 
have chronic otitis media was of 0.4 (CI95%: 0.2 – 0.9) 
times the risk of those who were under ART.
Only one (0.2%) 7 year old child who was not 
using HAART had acute otitis media complicated with 
otomastoiditis. Her CD4+ lymphocyte count was of 397 
x 10-9cel/L, and the use of intravenous antibiotics was 
efficient in curing her disease.
The average serum counts of CD4+ T lymphocytes 
Table 2. Distribution of the 459 children studied in the categories of im-
mune classification, according to age range and HAART use or not.
   Age range
0 to 5 years and 11 
months (n = 176)
6 to 12 years and 11 
months (n = 283)
Immune 
category
HAART
(n = 70)
ART
(n = 106)
HAART
(n = 153)
ART
(n = 130)
A1 12 (17,1%) 5 (4,7%) 54 (35,3%) 22 (16,9%)
A2 32 (45,7%) 21 (19,8%) 28 (18,3%) 13 (10,0%)
A3 1 (1,4%) - - -
B1 1 (1,4%) - 36 (23,5%) 24 (18,5%)
B2 19 (27,1%) 42 (39,6%) 24 (15,7%) 37 (28,5%)
B3 1 (1,4%) 3 (2,8%) - 1 (0,8%)
C1 - - 1 (0,7%) -
C2 3 (4,3%) 26 (24,5%) 7 (4,5%) 26 (20,0%)
C3 1 (1,4%) 9 (8,5%) 3 (2,0%) 7 (5,4%)
Table 3. Otorhinolaryngological diagnosis of the 459 Brazilian children 
infected with HIV.
Otorhinolaryngological Diagnosis n (%)
Otitis Media 152 (33,1%)
Chronic 65 (14,2%)
Acute 48 (10,5%)
Secretory 39 (8,5%)
Cholesteatoma 1 (0,2%)
Otomastoiditis 1 (0,2%)
Oral Lesion † 144 (31,6%)
Neck lymphadenopathy 70 (15,3%)
Sinusitis 66 (14,4%)
Chronic 36 (7,8%)
Acute 30 (6,5%)
Adenoid hypertrophy 44 (9,6%)
Rhinitis 43 (9,4%)
Tonsillitis 37 (8,1%)
Peritonsillar abscess 3 (0,7%)
Laryngitis (acute) 3 (0,7%)
Kaposi Sarcoma 1 (0,2%)
None 103 (22,5%)
† Includes Parotid Enlargement
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for each age range are depicted on Tables 5 and 6. Among 
the children with ages varying between 0 and 5 years and 
11 months, patients with COM had serum counts of CD4+ 
T cells of 150.5 ± 38 x 10-9 cell/L in average; below those 
without COM (p < 0.001).
Among the children between 6 and 12 years and 
11 months, there was no statistically significant difference 
regarding lymphocyte counts when we compared children 
with COM with those without it.
In general, children with ages between 6 and 12 
years and 11 months who had some type of otitis, had 
CD4+ counts of 75.5 38 x 10-9cel/L above the counts of 
other children (p = 0.002).
Children using HAART had average counts above 
that from those children using ART, regardless of age, and 
the differences were statistically significant (p < 0.001) 
– Table 7.
DISCUSSION
Ear diseases are particularly common in HIV-infect-
ed children, and it is one of the major causes of referrals 
to the otorhinolaryngologist16. Aside from it, HIV-infected 
children have otitis media more frequently and with 
greater severity than their immunecompetent couterparts8. 
In our series, otitis media was the most prevalent otorhi-
nolaryngological disease. On the other hand, reports in 
the otological infection literature in HIV-infected children 
under the HAART therapy are.
It is important to Record that all the patients 
included in the present study were receiving antiretro-
viral therapy, even if under heterogeneous therapeutic 
regimens. Since 1991, the Brazilian Government started to 
distribute Zidovudine free of charge for infected patients, 
and since 1996, by means of the Act 9313/96, 100% of 
infected patients have free access to antiretroviral therapy, 
including protease inhibitors.
The prevalence of chronic or acute otitis media in 
HIV-positive children in the literature varies. Chen et al. 
found a prevalence of 44% of recurrent otitis media in their 
series16. More recently, in South America, Bernaldez et al. 
found an incidence of 13.2% of suppurative chronic otitis 
media in HIV-infected children14. Now, Chandrasekhar 
et al. reported the presence of otorrhea in 5% of their 
HIV-infected patients17. Chaloryoo et al. found a general 
prevalence of otitis media in 18.4% in a group of 250 in-
fected Thai children18. Singh et al. noticed a prevalence of 
24% in a group of 107 children in London19. Hadfield et 
al., noticed a prevalence of 26% of acute otitis media and 
7.5% of chronic otitis media in 66 children they followed 
for 8 years20. Such data is similar to what we found in the 
present study, in which we found a prevalence of 10.5% 
for AOM, 14.2% for COM and 8.5% for SOM.
As to the influence of antiretroviral therapy in the 
Table 4. Chronic otitis media prevalence among the children in the 
study, according to age and HAART use or not.
Age range
0 to 5 years and 11 
months
6 to 12 years and 11 
months
HAART
(n=70)
ART p HAART ART p
Otite 
Média 
Crônica
5 
(7,1%)
22 
(20,8%)
0,02
20 
(13,1%)
18 
(13,8%)
0,86
HAART = Highly Active Antiretroviral Therapy; ART = Antiretroviral 
Therapy
Table 5. CD4+ T lymphocyte serum count according to the presence 
of chronic otitis media in children aged between 0 and 5 years and 
11 months.
0 to 5 years and 11 months
(n = 176)
CD4+ (x10-9cel/L) count p
Chronic Otitis 
Media
Yes (n = 27) 658,2 ± 189,5
<0,001
No (n = 149) 808,7 ± 179,9
Table 6. CD4+ T lymphocyte serum count according to the presence 
of chronic otitis media in children aged between 6 and 12 years and 
11 months.
6 to 12 years and 11 months
(n = 283)
CD4+ (x10-9cel/L) Count p
Chronic Otitis Media
Yes (n = 38) 492,5 ± 163,6
0,7
No (n = 245) 505,4 ± 188,4
Table 7. CD4+ T Lymphocyte count according to age range and the 
use of HAART.
                 Age Range
0 to 5 years and 11 
months
(n = 176)
6 to 12 years and 11 
months
(n = 283)
CD4+
(x109cel/L)
p
CD4+
(x109cel/L)
p
HAART 
(n = 223)
872,7 ± 158,1
<0,001
539,1 ± 
166,8
<0,001
ART
(n = 236)
728,1 ± 186,0
461,9 ± 
197,1
HAART = Highly Active Antiretroviral Therapy; ART = Antiretroviral 
Therapy
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prevalence of otitis media in HIV-positive patients, Zuc-
cotti et al. did not find statistically significant differences 
regarding the number of AOM episodes among children 
using or not antiretroviral therapy21.
Contrary to this, in our study, the use of HAART by 
HIV-positive children was associated to a lower prevalence 
of COM and greater prevalence of AOM, among children 
in the age range between 0 and 5 years and 11 months 
of age. As to SOM we did not notice any difference in 
prevalence among any age range studied, regardless of 
the use or not of the HAART therapy.
The relationship between clinical stage of the HIV 
infection, CD4+ lymphocyte count and otitis media was 
investigated by some authors. Chen et al. in their series 
have described a greater risk of otitis media infections as 
children progressed to more advanced clinical and im-
munological stages of the disease16. Makokha et al., in 
Kenya, showed the presence of acute otitis media in HIV-
infected children associated to a low CD4+ T cell count22. 
Barnett et al. had already reported that children with low 
CD4+ lymphocyte counts had higher risk of presenting 
recurrent otitis media9. Such data is in disagreement with 
those we found, since in our series, children under the 
HAART therapy with greater CD4+ T lymphocyte counts 
had greater AOM prevalence.
Moreover, the COM pathogenesis is multifactorial: 
environmental factors, genetically determined factors and 
functional/anatomical characteristics of the Eustachian 
Tube, all play a role13. G (IgG) and A (IgA) immunoglobu-
lins are important in the defense mechanisms against COM. 
There seems to be evidences of a regulatory role played 
by CD4+ T cells and interleukins 2 and 4 (IL-2 and IL-4) in 
the conversion of acute to chronic stages of OM, specially 
in cases of SOM23,24.
On the other hand, local mucosa immunity plays 
an important role in the microecology of the nasopharynx 
bacterial flora, and the HIV-infected children seem to have 
a severe local immune disorder11.
In our study, the HAART therapy has allowed for 
a better cellular immunity due to a significant increase in 
the count of CD4+ lymphocytes in both age ranges, and 
such fact was also observed by other authors4,5,25,26. This 
may have been one of the reasons that led the children 
under HAART, aged bellow 6 years to present lower COM 
incidence.
Another important point to be stressed in our study 
is the fact that we found only one child with complica-
tions accruing from otitis media (otomastoiditis). The 
literature states that otitis media tends to be more severe 
in the immunesupressed population with greater rates of 
complications, specially bacteremia6,9,11,16. It is possible that 
this reduction seen in the incidence be secondary to the 
immunological improvement caused by HAART.
FINAL COMMENTS
Since this is a transversal study, based on a single 
evaluation of patients, the major limitation we had is in 
establishing only associations between the data and not 
necessarily causality. Another possible limitation is that 
we do not control data related to HIV-1 RNA levels (viral 
burden), which were not available for all patients.
Thus, based on the data presented here, we con-
clude that the HAART therapy in HIV-infected children 
below 6 years of age was associated to a lower prevalence 
of chronic otitis media, probably due to an increase in 
their CD4+ T lymphocyte counts.
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